Chester County News and Community Website
Galera Therapeutics, Inc. (Nasdaq: GRTX), headquartered in Malvern, PA, is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.
MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) this week announced the appointment of accomplished pharmaceutical sales, market access, and commercial operations executives to Galera’s senior commercial leadership team, effective …
Galera Expands Commercial Leadership Team Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that a prespecified analysis from the Phase 3 ROMAN trial detailing one-year reductions in cisplatin-related chronic kidney disease in patients with …
Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced the recent presentation on Friday, March 10, 2023, of a net treatment benefit analysis of Phase 3 ROMAN results at the …
Groundbreaking SOM Analysis by Galera Presented at ECHNO Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) this week announced financial results for the fourth quarter and year ended December 31, 2022 and provided recent corporate updates.
Galera Reports Fourth Quarter and Full Year 2022 Financial Results Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted priority review to the New Drug Application …
Galera Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral Mucositis Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) this week announced that it has agreed to sell 14,320,000 shares of common stock and warrants to purchase up to 14,320,000 shares …
Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants Read More